Xigris (Zy-gris, drotrecogin alfa), a new biotech drug for treating severe sepsis

January 2002

Lilly is now marketing Xigris (Zy-gris, drotrecogin alfa), a new biotech drug for treating severe sepsis.

Until now the main treatment for severe sepsis was antibiotics.

Xigris is the first drug shown to improve survival in cases of severe septic infections. It reduces deaths by about 6%...or saves one life for every 16 patients who are treated.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote